Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

Keros Therapeutics (Nasdaq: KROS) announced that President and CEO Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET.

Rhea-AI Summary

Keros Therapeutics (Nasdaq: KROS) announced that President and CEO Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET.

A live audio webcast will be available via Goldman Sachs and an archived replay will be accessible in the Investors section of the Keros website for up to 90 days.

Argus Jun 2 session

-3.21% close to close Open Argus

Details

News Market Reaction – KROS

In the Jun 2 session, KROS declined 3.21%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement describes Keros’ participation in a Goldman Sachs healthcare conference, including...

Analysis

This announcement describes Keros’ participation in a Goldman Sachs healthcare conference, including a fireside chat on June 8, 2026 at 4:00 p.m. ET and a webcast replay available for 90 days. In recent months, earnings reports on Feb 26 and May 14, along with clinical and partnership updates, have been more material drivers. Investors tracking the story may focus on any qualitative commentary from the event alongside upcoming financial results and clinical milestones.

Key Figures

Conference edition: 47th Conference date: June 8, 2026 Presentation time: 4:00 p.m. ET +1 more

Conference edition

47th

Goldman Sachs Annual Global Healthcare Conference

Conference date

June 8, 2026

Scheduled fireside chat presentation

Presentation time

4:00 p.m. ET

Start time of fireside chat

Replay period

90 days

Archived webcast available on investor website

Historical Context

5 past events · Latest: May 14

5 events

1. May 14

   Earnings update

   24h Move

   -8.3%

   Q1 2026 results showed return to losses after prior Takeda-driven income.

2. Mar 09

   Partnership deal

   24h Move

   +0.4%

   ALS trial collaboration with Mass General under Healey ALS MyMatch program.

3. Mar 09

   Clinical data update

   24h Move

   +0.4%

   Additional Phase 1 rinvatercept data showing tolerability and biomarker effects.

4. Mar 04

   Earnings update

   24h Move

   -15.0%

   Q4 and 2025 results with net income driven by Takeda license revenue.

5. Feb 26

   Board change

   24h Move

   -5.6%

   Appointment of Charles Newton and departure of Carl Gordon from board.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

transforming growth factor-beta, tgf-ß

2 terms

transforming growth factor-beta medical

"disorders that are linked to dysfunctional signaling of the transforming growth factor-beta"

Transforming growth factor-beta (TGF-β) is a naturally occurring signaling protein that helps control cell growth, inflammation and tissue repair, acting like a traffic cop that tells cells when to divide, change form or calm down. It matters to investors because drugs that block or boost TGF-β can treat cancers, fibrotic diseases and immune disorders, affecting clinical trial outcomes, regulatory risk and the commercial potential of biopharma assets.

tgf-ß medical

"dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins"

Transforming growth factor beta (TGF-ß) is a naturally occurring protein that helps cells talk to each other and controls processes like growth, scarring and immune response. Think of it as a traffic signal for tissues that can either slow down or redirect cell behavior. Investors watch TGF-ß because drugs that change its signals can treat cancer, fibrosis and immune diseases, so changes in research results or regulatory news can strongly affect a biotech’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time.

A live audio webcast of the fireside chat presentation will be available at https://cc.webcasts.com/gold006/060826a_js/?entity=146_YVQJ8LJ and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Keros Therapeutics (KROS) present at the Goldman Sachs 47th Annual Global Healthcare Conference?

Keros Therapeutics will present a fireside chat on Monday, June 8, 2026 at 4:00 p.m. Eastern time. According to Keros, President and CEO Jasbir S. Seehra, Ph.D., will represent the company at the event.

Who will represent Keros Therapeutics (KROS) at the Goldman Sachs 2026 healthcare conference?

Keros Therapeutics will be represented by President and CEO Jasbir S. Seehra, Ph.D. in a fireside chat. According to Keros, he will speak at the Goldman Sachs 47th Annual Global Healthcare Conference.

How can investors listen to the Keros Therapeutics (KROS) fireside chat at Goldman Sachs 2026 conference?

Investors can access a live audio webcast of the Keros fireside chat via the Goldman Sachs webcast link. According to Keros, an archived replay will also be available on its investor relations website.

Where will the replay of the Keros Therapeutics (KROS) Goldman Sachs conference webcast be available?

The replay will be accessible in the Investors section of the Keros Therapeutics website. According to Keros, the archived fireside chat webcast will remain available for up to 90 days after the event.

What type of event will Keros Therapeutics (KROS) hold at the Goldman Sachs 47th Annual Global Healthcare Conference?

Keros Therapeutics will participate in a fireside chat presentation at the conference. According to Keros, this discussion will feature President and CEO Jasbir S. Seehra, Ph.D., and will be streamed via live audio webcast.